Search clinical trials for: HIV-1 capsid inhibitor

Total 109843 results

AIDS Clinical Trials Group
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Effect of Isotretinoin on Immune Activation Among HIV-1 Infected Subjects With Incomplete CD4+ T Cell Recovery

HIV-1 Infection

United States, Puerto Rico
Azienda Ospedaliera Universitaria Integrata Verona

Completed

Short Cycle Therapy in ART Regimens Containing Rilpivirine: Assessment of Patients' Satisfaction

HIV-1-infection

Italy
Rockefeller University
National Institute of Allergy and Infectious Diseases (NIAID); Montefiore Medical... and other collaborators

Completed

A Study of the Safety and Antiretroviral Activity of 3BNC117

HIV-1 Infection

United States
Merck Sharp & Dohme LLC

Completed

Safety, Tolerability, Pharmacokinetics, and Anti-Retroviral Activity of MK-8558 Monotherapy in Anti-Retroviral-Naïve HIV-1 Infected Participants (MK-8558-002)

HIV-1 Infection

Germany, Romania
Gilead Sciences

Completed

Study to Evaluate Safety, Pharmacokinetics, and Antiviral Activity of Lenacapavir Administered Subcutaneously in Human Immunodeficiency Virus (HIV) -1 Infected Adults

HIV-1 Infection

United States
Gilead Sciences

Completed

Study to Evaluate Switching From an E/C/F/TAF Fixed-Dose Combination (FDC) Regimen or a TDF Containing Regimen to B/F/TAF FDC in Human Immunodeficiency Virus-1 (HIV-1) Infected Participants Aged ≥ 65 Years

HIV-1 Infection

Spain, United Kingdom, France, Italy, Belgium
Gilead Sciences

Completed

Switch Study to Evaluate F/TAF in HIV-1 Positive Participants Who Are Virologically Suppressed on Regimens Containing FTC/TDF

HIV-1 Infection

United States, United Kingdom, Canada, France, Italy, Puerto Rico, Belgium
Gilead Sciences

Completed

Safety and Efficacy of Switching to a FDC of B/F/TAF From E/C/F/TAF, E/C/F/TDF, or ATV+RTV+FTC/TDF in Virologically Suppressed HIV-1 Infected Women

HIV-1 Infection

Russian Federation, United States, Thailand, Uganda, Puerto Rico, Dominican Republic
United BioPharma

Withdrawn

the Study to Evaluate the Safety of UB-421 in Combination With Antiretroviral Therapy (ART) and the Efficacy in Reduction of HIV Viral Load and Proviral DNA as Compared to ART Alone in ART-experienced Viremic HIV-1 Patients

HIV-1 Infection
Fundación FLS de Lucha Contra el Sida, las Enfermedades...

Completed

Pilot Study to Assess the Impact of a Mobile Health Application (App) on Clinical Outcomes and Satisfaction of Older HIV-Infected Patients, as an Emerging Tool for Care, Education and Prevention.

HIV-1 Infection

Spain
Asociación Civil Impacta Salud y Educación, Peru
amfAR, The Foundation for AIDS Research; The Fenway Institute; Epicentro

Completed

Gender-Affirmative Transgender Care to Improve the HIV Treatment Cascade

HIV-1-infection

Peru
Gilead Sciences

Completed

Safety and Efficacy of Switching From Regimens of ABC/3TC + a 3rd Agent to E/C/F/TAF Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV 1 Infected Adults

HIV-1 Infection

Spain, United Kingdom, France, Germany, United States, Italy
AIDS Clinical Trials Group
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

High Dose Vitamin D and Calcium for Bone Health in Individuals Initiating HAART

HIV-1 Infection

United States, Puerto Rico
Merck Sharp & Dohme LLC

Terminated

Study of MK-1972 in Human Immunodeficiency Virus (HIV)-1 Infected Participants Who Have Not Previously Received Antiretroviral Therapy (MK-1972-003)

HIV-1 Infection
United BioPharma
Kaohsiung Medical University Chung-Ho Memorial Hospital; Taipei Veterans General... and other collaborators

Completed

To Investigate the Safety and Efficacy of UB-421 Monotherapy in HIV Infected Adults

HIV-1 Infection

Taiwan
Affiliated Hospital to Academy of Military Medical...
Peking University; Capital Medical University

Unknown

Safety of Transplantation of CRISPR CCR5 Modified CD34+ Cells in HIV-infected Subjects With Hematological Malignances

HIV-1-infection

China
International Partnership for Microbicides, Inc.

Withdrawn

Dapivirine Gel Rectal Safety and PK Study

HIV 1 Infection

United States
Merck Sharp & Dohme LLC

Completed

A Study of Safety, Tolerability and Immunogenicity of a 1-Dose Regimen of MRKAd5 HIV-1 Gag Vaccine Versus the ALVAC_HIV Vaccine (V520-019)

HIV-1 Infection
University of Oxford

Completed

Safety and Immunogenicity Study of Three Candidate HIV-1 Vaccines, Administered in Combination to Healthy HIV-1 Uninfected Adults (HIV-CORE 002)

HIV-1 Infections

United Kingdom
Bionor Immuno AS

Completed

Immunotherapy With Vacc-C5 With Adjuvant GM-CSF or Alhydrogel in HIV-1-infected Subjects on ART

HIV-1 Infection

Norway
Imperial College London
Medical Research Council

Terminated

Novel Interventions in HIV-1 Infection (IMIRC1003)

HIV-1 Infection

United Kingdom
Objectif Recherche Vaccins SIDA
Merck Sharp & Dohme LLC; Pfizer; Cytheris SA

Completed

Therapeutic Intensification Plus Immunomodulation in HIV-infected Patients (ERAMUNE-01)

HIV-1 Infection

United Kingdom, France, Italy, Spain
Objectif Recherche Vaccins SIDA

Completed

Exploration of HIV Reservoirs (MUCOVIR)

HIV-1 Infection

France
Philip Grant

Withdrawn

Effect of Reducing Nucleotide Exposure on Bone Health (ReNew) (ReNew)

HIV/AIDS | Osteopenia | HIV-1-infection

United States
United Biomedical
Taipei Veterans General Hospital, Taiwan; Kaohsiung Veterans General Hospital. and other collaborators

Completed

Study to Evaluate Safety and Efficacy of UB-421 Antibody in HIV-1 Infected Adults

HIV-1 Infection in Adults

Taiwan
St Stephens Aids Trust

Terminated

Impact of Maraviroc on the Immune Function in HIV-1 Infected Subjects Receiving Immunisation With Novel Antigens

HIV Infections

United Kingdom
Peking Union Medical College
Ministry of Science and Technology of the People´s Republic of China

Unknown

Study on the Impact of Triptolide Woldifiion on HIV-1 Reservoir In Acute HIV-1 Infection

AIDS/HIV PROBLEM

China
GlaxoSmithKline

Completed

A Study of an Investigational Regimen Combining FDA Approved HIV Drugs in HIV-Infected Subjects

HIV Infection | Infection, Human Immunodeficiency Virus

United States, Puerto Rico
Gilead Sciences

Not yet recruiting

A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments

HIV-1-infection
Chelsea and Westminster NHS Foundation Trust

Recruiting

Efficacy of Doravirine + Dolutegravir Dual Therapy in the Context of Antiretroviral Therapy Switch (DORDOL)

HIV-1-infection

United Kingdom
IrsiCaixa

Completed

Impact of Raltegravir Intensification on HIV-1-infected Subjects With Complete Viral Suppression Under Monotherapy With Protease Inhibitors

HIV-1 Infection

Spain
Quest Clinical Research
Gilead Sciences

Completed

Bictegravir/Emtricitabine/Tenofovir Alafenide Plus Doravirine

HIV-1-infection

United States
Merck Sharp & Dohme LLC

Completed

Doravirine/Islatravir (DOR/ISL) in Pediatric Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are <18 Years of Age and Weigh ≥35 kg (MK-8591A-028)

HIV-1 Infection

United States, Italy, Russian Federation, South Africa, Thailand
Merck Sharp & Dohme LLC

Active, not recruiting

Study of Doravirine/Islatravir (DOR/ISL 100 mg/0.75 mg) to Evaluate the Antiretroviral Activity, Safety, and Tolerability in Treatment-Naïve Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591A-020)

HIV-1 Infection

United States, Argentina, Canada, Chile, Colombia, France, Germany, Israel, Italy, Japan, South Africa, Spain, Taiwan
Professor Francois Venter

Completed

DORA: A Doravirine-based First-line Antiretroviral Therapy for Women of Reproductive Potential Living With HIV (DORA)

HIV-1-infection

South Africa
Gilead Sciences

Completed

D/C/F/TAF Versus COBI-boosted DRV Plus FTC/TDF in HIV-1 Infected, Antiretroviral Treatment Naive Adults

HIV Infections | Acquired Immunodeficiency Syndrome

United States, Puerto Rico
National Institute of Allergy and Infectious Diseases...

Completed

A Phase I, Multicenter, Randomized Trial to Evaluate the Safety and Immunogenicity of a Recombinant Vaccinia-HIV Envelope Vaccine (HIVAC-1e) in Combination With a Panel of Subunit Recombinant HIV Envelope Vaccines in Vaccinia-Naive Individuals

HIV Infections

United States
Duke University
GlaxoSmithKline

Completed

A Randomized, Prospective Study of the Efficacy, Safety and Tolerability of Two Doses of GW433908Ritonavir Given With Abacavir/Lamivudine Fixed Dose Combination

HIV

United States
TaiMed Biologics Inc.
Bill and Melinda Gates Foundation; Aaron Diamond AIDS Research Center

Completed

Safety Study of Ibalizumab Subcutaneous Injection in Healthy Volunteers (TMB-108)

Prevention of Infection With HIV-1

United States
Merck Sharp & Dohme LLC

Recruiting

DOR/ISL in HIV-1 Antiretroviral Treatment-naïve Participants (MK-8591A-053)

HIV-1 Infection

United States, Israel, Puerto Rico, Japan, South Africa, Chile, Thailand, United Kingdom, Argentina, Colombia, France, Germany, Malaysia, Spain, Switzerland, Guatemala, Turkey, Canada, Dominican Republic
University of Aarhus
Aarhus University Hospital; The Alfred; The Peter Doherty Institute for Infection... and other collaborators

Recruiting

Administration of Venetoclax to Promote Apoptosis of HIV-infected Cells and Reduce the Size of the HIV Reservoir Among People Living With HIV on ART (AMBER)

HIV-1-infection

Denmark
MRC/UVRI and LSHTM Uganda Research Unit
Janssen Pharmaceuticals

Recruiting

Improving HIV-1 Control in Africa With Long Acting Antiretrovirals (IMPALA)

HIV-1-infection

South Africa, Kenya, Uganda
Orlando Immunology Center
ViiV Healthcare

Recruiting

Changes in Immunologic Parameters Following the Addition of Fostemsavir in Virologically Suppressed Immunologic Non-responders Living With HIV-the RECOVER Study

HIV-1-infection

United States
University of California, San Francisco
Merck Sharp & Dohme LLC

Recruiting

Pharmacokinetics Distribution of Raltegravir by PET/MR

HIV-1-infection

United States
Merck Sharp & Dohme LLC

Active, not recruiting

Dose Ranging, Switch Study of Islatravir (ISL) and Ulonivirine (MK-8507) Once-Weekly in Virologically-Suppressed Adults With Human Immunodeficiency Virus Type 1 (HIV-1) [MK-8591-013]

HIV-1 Infection

United States, France, Switzerland
Fundación FLS de Lucha Contra el Sida, las Enfermedades...

Active, not recruiting

Implementation of Out-of-HOspital Administration of the Long-Acting Cabotegravir+Rilpivirine (HOLA)

HIV-1 Infection

Spain
Merck Sharp & Dohme LLC

Active, not recruiting

A Switch to Doravirine/Islatravir (DOR/ISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are Virologically Suppressed on Antiretroviral Therapy (ART) (MK-8591A-051)

HIV-1 Infection

United States, Australia, Canada, Colombia, Japan, South Africa, Switzerland, United Kingdom
Instituto de Investigación Sanitaria de la Fundación...

Completed

REal-Life Cohort With DOlutegravir + LAmivudina (REDOLA)

HIV-1-infection

Spain
Massachusetts General Hospital
Harvard Medical School (HMS and HSDM); National Institute of Allergy and Infectious... and other collaborators

Completed

Population Effectiveness of Dolutegravir Implementation in Sub-Saharan Africa (DISCO)

HIV-1-infection

Uganda, South Africa
Gilead Sciences

Completed

Study to Evaluate the Safety and Efficacy of Lenacapavir in Combination With Other Antiretroviral Agents in People Living With HIV (CALIBRATE)

HIV-1-infection

United States, Puerto Rico, Dominican Republic

3

Subscribe